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Abstract
Introduction: CXCL12-CXCR4 signaling has been shown to play a role in breast cancer progression by enhancing
tumor growth, angiogenesis, triggering cancer cell invasion in vitro, and guiding cancer cells to their sites of
metastasis. However, CXCR7 also binds to CXCL12 and has been recently found to enhance lung and breast
primary tumor growth, as well as metastasis formation. Our goal was to dissect the contributions of CXCR4 and
CXCR7 to the different steps of metastasis - in vivo invasion, intravasation and metastasis formation.
Methods: We overexpressed CXCR4, CXCR7 or both in the rat mammary adenocarcinoma cell line MTLn3. Stable
expressors were used to form tumors in severe combined immunodeficiency (SCID) mice, and in vivo invasiveness,
intravital motility, intravasation, and metastasis were measured.
Results: We found that CXCR4 overexpression increased the chemotactic and invasive behavior of MTLn3 cells to
CXCL12, both in vitro and in vivo, as well as in vivo motility and intravasation. CXCR7 overexpression enhanced
primary tumor growth and angiogenesis (as indicated by microvessel density and VEGFA expression), but
decreased in vivo invasion, intravasation, and metastasis formation. In vitro, expression of CXCR7 alone had no
effect in chemotaxis or invasion to CXCL12. However, in the context of increased CXCR4 expression, CXCR7
enhanced chemotaxis to CXCL12 but decreased invasion in response to CXCL12 in vitro and in vivo and impaired
CXCL12 stimulated matrix degradation. The changes in matrix degradation correlated with expression of matrix
metalloproteinase 12 (MMP12).
Conclusions: We find that CXCR4 and CXCR7 play different roles in metastasis, with CXCR4 mediating breast
cancer invasion and CXCR7 impairing invasion but enhancing primary tumor growth through angiogenesis.
Introduction
There are currently two known receptors for CXCL12:
CXCR4 and CXCR7 [1,2], which belong to the family of
G-protein coupled receptors (GPCRs). CXCR4 is
expressed in several human cancers including glioma
[3], neuroblastoma [4], pancreatic [5] and breast [6],
with overexpression of CXCR4 in breast cancer correlat-
ing with poor patient prognosis [7-9]. CXCL12/CXCR4
signaling has been reported to stimulate growth of sev-
eral tumors including breast [10-13], with carcinoma-
associated fibroblasts (CAFs) being an important source
of CXCL12 in the tumor microenvironment [14]. CAFs
can enhance tumor growth in a paracrine manner, with
secreted CXCL12 directly stimulating growth of CXCR4
expressing breast cancer cells, and in an endocrine man-
ner, recruiting endothelial progenitor cells (EPCs) to the
primary tumors, thus enhancing angiogenesis [15].
CXCL12, also known as SDF-1, belongs to the CXC
family of chemokines. CXCL12 functions as a growth
factor for B cell progenitors [16], a chemotactic factor
for both T cells and monocytes, a regulator of hemato-
poiesis and as a chemoattractant for tissue-committed
stem cells [17,18]. Importantly, CXCL12 has been found
to be expressed in many human solid tumors including
breast, pancreas and prostate cancers, and glioblastoma
[17], with high levels of CXCL12 expression correlating
with poor prognosis of breast cancer patients [19].
CXCL12/CXCR4 signaling has been shown to stimu-
late the chemotactic and invasive behavior of breast can-
cer cells in vitro and in vivo [6,10,19-21], and has been
proposed to serve as a homing mechanism for cancer
cells to sites of metastasis. CXCL12 is expressed at high
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levels in the bone marrow, lung, liver, and lymph nodes,
common sites of breast cancer metastasis, with protein
extracts from these organs stimulating chemotaxis of
breast cancer cells in a CXCR4-dependent manner [6].
Furthermore, downregulation of CXCR4 signaling using
a neutralizing antibody or miRNA, decreases sponta-
neous and experimental lung metastasis formation of
MDA-MB-231 cells [6,20].
Like CXCR4, CXCR7 is also expressed in different
human cancers, including breast, being highly expressed
in the tumor vasculature [22,23]. CXCR7 is considered
an atypical GPCR because ligand binding does not result
in intracellular Ca2+ release [2,24], and there are con-
flicting reports on the ability of CXCR7 to activate
phosphatidylinositol 3-kinase (PI3K) or mitogen-acti-
vated protein kinase (MAPK) signaling, and to promote
cell motility. Binding of CXCL12 or interferon-inducible
T-cell alpha chemoattractant (I-TAC/CXCL11), the
other known CXCR7 ligand, to CXCR7 activates PI3K
and MAPK signaling in astrocytes, Schwann cells, glio-
mas, rhabdomyosarcoma, and pancreatic cancer cells
[23-26]. Moreover, CXCR7 has been reported to med-
iate CXCL12 chemotaxis in T cells [1] and rhabdomyo-
sarcoma cells [26], and to promote hepatocellular
carcinoma invasion in vitro [27]. However, other studies
have shown that CXCR7 does not play a role in bare fil-
ter migration but in transendothelial migration [28], and
that CXCR7 plays no role in T cell chemotaxis or
MAPK/PI3K signaling [29]. Although the interaction of
CXCR7 with G proteins is controversial, new studies
have found that CXCR7 binds to b-arrestin 2, with this
interaction resulting in receptor internalization
[28,30,31], and mediating chemotaxis to I-TAC in vas-
cular smooth muscle cells [32]. Furthermore, CXCR4
and CXCR7 can form both homodimers and heterodi-
mers with heterodimer formation suggested to modulate
CXCR4 signaling both positively, and negatively [33-35].
Most recently, CXCR4+CXCR7+ MDA MB 231 cells
have been shown to chemotax in response to CXCL12
stimulation better than 231 cells expressing only
CXCR4, with this chemotactic response being depen-
dent on b-arrestin 2 [36].
CXCR7 has been implicated in enhancing cancer cell
adhesion to fibronectin and endothelial cells [2,23,27];
increasing cell survival by decreasing apoptosis [2,23]
and promoting primary tumor growth of lymphoma,
lung, breast, prostate and hepatocellular cancer cells
[2,22,23,27]. CXCR7 expression has been reported to
contribute to tumor angiogenesis through the secretion
of angiogenic factors such as vascular endothelial
growth factor (VEGF) [23,27], as well as to promote
experimental metastasis formation of breast cancer cells
[22].
Although CXCL12 signaling has been implicated in
breast cancer metastasis as a homing mechanism for
cancer cells to common sites of metastasis, not much is
currently known about the role of CXCL12 signaling in
the early steps of metastasis within the primary tumor.
Also, the role of CXCR7 in breast cancer cell motility,
tumor growth and metastasis is still unclear, with the
effect of coexpression of CXCR4 and CXCR7 in these
processes mostly unknown. With research suggesting
that both CXCR4 and CXCR7 alone can enhance metas-
tasis, we set out to dissect the roles of CXCR4 and
CXCR7 in the different steps of metastasis (invasion,
intravasation, and metastasis formation) by overexpres-
sing CXCR4, CXCR7, or both receptors in the rat mam-
mary adenocarcinoma cell line MTLn3. Here we report
that CXCR4 overexpression increases the chemotactic
and invasive behavior of MTLn3 cells, in vitro and in
vivo, to CXCL12, as well as their motile behavior within
the primary tumor. Furthermore, although CXCR4 over-
expression had no effect on primary tumor growth, it
enhanced intravasation without affecting spontaneous
lung metastasis formation. CXCR7 overexpression alone
did not result in CXCL12-induced chemotaxis or inva-
sion in vitro; however, in the context of high CXCR4
expression it further increased the in vitro chemotactic
response of MTLn3 CXCR4 cells to CXCL12, while
reducing invasion and matrix degradation. In vivo,
CXCR7 increased primary tumor growth while it
impaired invasion to CXCL12, intravasation and sponta-
neous lung metastasis formation. CXCR7 overexpression
downregulated the effects of CXCR4 in motility within




All MTLn3 cell lines were grown in alpha MEM supple-
mented with 5% FBS (100-106; Gemini Bio-Products,
West Sacramento, CA, USA) and 0.5% penicillin/strep-
tomycin (15140-122; Invitrogen, Grand Island, NY,
USA). To create the human CXCR4 expressors,
hCXCR4 was transferred from the pDNR-Dual hCXCR4
vector (Harvard Institute of Proteomics, Boston, MA,
USA), to the JP1520 retroviral vector following the
Creator Cloning protocol, using Cre recombinase (Clon-
tech, Mountain View, CA, USA) and Max Efficiency
DH5alpha bacteria (Life Technologies, Grand Island,
NY, USA) grown in 7% sucrose, 30 μg/ml chloramphe-
nicol plates. Colonies were picked and correct insertion
of human CXCR4 verified by sequencing. The human
CXCR7 sequence was digested out from the pcDNA 3.1
+ plasmid (kindly provided by ChemoCentryx, Mountain
View, CA, USA) using NotI, the ends blunted using
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DNA Polymerase I, large Klenow fragment (NEB, Ips-
wich, MA, USA), to insert into JP1520, which was
digested with BamHI and BbsI removing the loxP site,
ends blunted as above and treated with Antarctic phos-
phatase (NEB, Ipswich, MA, USA). Both insert and vec-
tor were gel purified using the Qiagen Gel extraction
kit, then ligated using a Rapid DNA Ligation kit (Roche,
Branchburg, NJ, USA). Subcloning efficiency DH5alpha
bacteria (Life Technologies, Grand Island, NY, USA)
were transformed with the ligated vector and colonies
screened for correct insertion of hCXCR7 using differ-
ential enzyme digestions, followed by verification using
sequencing analysis. MTLn3-GFP (MTLn3 cells expres-
sing green fluorescent protein) cells were transduced
with either the empty JP1520 vector, JP1520-CXCR4,
JP1520-CXCR7, or both CXCR4 and CXCR7, by first
transfecting Phoenix packaging cells with 2 μg of each
vector using lipofectamine (Invitrogen, Grand Island,
NY, USA), collecting virus and transducing MTLn3-GFP
cells seeded at 60% confluency. Transduced cells were
selected with 1 μg/ml puromycin. MTLn3 CXCR7 and
MTLn3 CXCR4-CXCR7 cells were subsequently fluores-
cence-activated cell sorting (FACS) sorted in a DakoCy-
tomation MoFlo to obtain a homogenous population of
CXCR7 expressing cells. MDA MB 435 cell lines were
grown in DMEM (10-013 CV, Cellgro, Manassas, VA,
USA) supplemented with 10% FBS (S11550, Atlanta Bio-
logicals, Lawrenceville, GA, USA) and 0.5% penicillin/
streptomycin. 435 cells seeded at 60% confluency, were
transduced with either the empty JP1520 vector, JP1520-
CXCR4 or JP1520-CXCR7 using premade virus, with
transductants selected using 1 μg/ml puromycin. MDA
MB 435 CXCR7 cells were FACS sorted in a DakoCyto-
mation (Carpinteria, CA, USA) MoFlo to obtain a
homogenous population of CXCR7 expressing cells. The
435 double overexpressors, CXCR4-CXCR7, were made
by transducing sorted 435-CXCR7 cells with JP1520-
CXCR4 virus and then FACS sorted for high CXCR4
expression. MDA MB 435 CXCR4 cells were sorted at
the same time to obtain cell lines with homogenous
CXCR4 expression.
Reverse transcription and PCR
MTLn3 cells grown to 70 to 85% confluency were used
for RNA isolation using the Qiagen RNeasy Mini kit
with DNase I treatment (Valencia, CA, USA). A 1 μg
sample of total RNA was used for reverse transcription
using Superscript III and random hexamers in a 20 μl
reaction volume. A 2 μl aliquot of the reaction was used
for PCR using Taq polymerase for 30 cycles. Primers
used were: rat glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH) (PPR06557A Superarray), rat CXCR4 (5’
AGGAACTGAACGCTCCAGAA 3’ and 5’ AACCACA-
CAGCACAACCAAA 3’), human CXCR4 (5’
CTCCAAGCTGTCACACTCCA 3’ and 5’ TCGATGCT-
GATCCCAATGTA 3’), human and rat CXCR7 (5’
GCACTACATCCCGTTCACCT 3’ and 5’AAGGCCTT-
CATCAGCTCGTA 3’). PCR products were run in a
1.5% agarose gel containing ethidinium bromide. For
quantitation of endogenous expression of rat CXCR4,
the collected cDNA was used for quantitative real-time
PCR with SYBR Green (PA-012, SuperArray Biosciences,
Frederick, MD, USA) and an Applied Biosystems
7900HT (Carlsbad, CA, USA). To evaluate the expres-
sion of matrix metalloproteinases (MMPs) in the differ-
ent MTLn3 transductants, the cell lines were grown to
80 to 90% confluency in six-well plates, starved over-
night in alpha-MEM/0.35% BSA in a 37°C incubator,
and then stimulated for four hours with 10 nM CXCL12
(460-SD; R&D systems, Minneapolis, MN, USA) in
alpha-MEM/0.35% BSA or just alpha-MEM/0.35% BSA
at 37°C. RNA was extracted using the Qiagen RNeasy
Mini kit with DNase I treatment. A 2 μg sample of total
RNA was used for reverse transcription using a Super-
script First Strand kit (11904-018, Invitrogen, Grand
Island, NY, USA) and cDNA used for real time PCR
with SYBR Green (PA-012) on an Applied Biosystems
7900HT. Rat specific primers for MMPs were obtained
from real-time primers (Elkins Park, PA, USA). RNA
expression of MMPs was normalized to GAPDH.
Fluorescent activated cell sorting (FACS)
To analyze the levels of CXCR4 and CXCR7 expres-
sion in the MTLn3 and MDA MB 435 cell lines, cells
were grown to 80% confluency, detached at 37°C using
PBS without Ca2+/Mg2+ +2 mM ethylenediaminetetraa-
cetic acid (EDTA) and resuspended in 1 ml cold PBS
without Ca2+/Mg2+ supplemented with 0.2% BSA. Cells
were labeled with either control mouse IgG antibody
(MAB002; R&D systems, Minneapolis, MN, USA),
anti-human CXCR4 antibody (MAB172; R&D systems,
Minneapolis, MN, USA) or anti-human CXCR7 anti-
body (11G8; ChemoCentryx, Mountain View, CA,
USA) for 45 minutes at 4°C. Unbound primary anti-
body was removed by washing and bound antibody
was detected with APC antimouse secondary antibody
(Jackson ImmunoResearch, West Grove, PA, USA).
Expression of rat CXCR4 protein was evaluated in the
MTLn3 transductants using a rat specific CXCR4 anti-
body (ab7199, Abcam, Cambridge, MA, USA) with a
rabbit IgG as a control (011-000-003, Jackson Immu-
noResearch, West Grove, PA, USA) and anti-rabbit
DyLight 649 as the secondary antibody (111-496-144,
Jackson ImmunoResearch, West Grove, PA, USA).
Fluorescently labeled cells were evaluated using a Bec-
ton Dickinson LSRII (Franklin Lakes, NJ, USA). FCS
files were analyzed using FlowJo software (Ashland,
OR, USA).
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In vitro chemotaxis
Chemotaxis was evaluated using a 48-well microchemo-
taxis chamber (Neuroprobe, Gaithersburg, MD, USA)
and PVP-free 8 μm pore polycarbonate filters (Neurop-
robe, Gaithersburg, MD, USA) coated with 27 μg/ml rat
tail collagen type I (BD Bioscience, Franklin Lakes, NJ,
USA). Cell lines were starved in L15 medium supple-
mented with 0.35% BSA for three hours at 37°C,
detached using PBS without Ca2+/Mg2+ + 2 mM EDTA
and resuspended in L15-0.35% BSA to plate 2 × 104
cells per well for MTLn3 transductants, or 1.5 × 104
cells per well for the MDA MB 435 transductants.
CXCL12 solutions were prepared in L15-0.35% BSA and
placed in the bottom wells with cells plated in the top
wells of the assembled chamber. To inhibit CXCL12
binding to CXCR7, we added 10 nM I-TAC (572-MC;
R&D systems, Minneapolis, MN, USA), or used the
CXCR7 inhibitors CCX733 (ChemoCentryx, Mountain
View, CA, USA) and CCX771 (ChemoCentryx, Moun-
tain View, CA, USA) added to both top and bottom
wells, including vehicle (DMSO) as a control. To inhibit
CXCR4, we added AMD3100 (Sigma, St. Louis, MO,
USA) to both top and bottom wells. After a four-hour
incubation at 37°C, filters were placed in 10% formalin
solution to fix the cells for 30 minutes, cells on the top
of the filter, non-migrating cells, were removed using a
cotton swab, and migrating cells subsequently stained
overnight in hematoxylin. The number of cells crossing
the filter in one representative 10× field was counted
per well for the MTLn3 transductants, using a Nikon
Labophot light microscope (Melville, NY, USA), and
corresponding wells averaged per experiment. To deter-
mine MDA MB 435 chemotaxis, the number of cells
that crossed each well were counted and corresponding
wells averaged per experiment.
In vitro invasion
MTLn3 transductants grown to 70 to 85% confluency
were starved for three hours in alpha-MEM supplemen-
ted with 0.35% BSA in a 37°C incubator. Cells were
detached using PBS without Ca2+/Mg2+ containing 2
mM EDTA, resuspended in alpha-MEM supplemented
with 0.35% BSA to plate 1 × 105 cells in a 500 μl
volume on top of Matrigel-precoated 8 μm pore-filters
(354480; BD Biosciences transwells, Franklin Lakes, NJ,
USA) that had been equilibrated for one hour with
alpha-MEM/0.35% BSA in a 37°C incubator. Cells were
allowed to invade overnight in a 37°C incubator in
response to either alpha-MEM/0.35% BSA alone or con-
taining 10 nM CXCL12. The filters were fixed in 10%
formalin for 30 minutes and stained with crystal violet
for 15 minutes. Cells that had not invaded were
removed with a cotton tip applicator from the top of
the filter, filters removed, placed in a coverslip and the
total number of invading cells present in a filter counted
using a Nikon Labophot light microscope with a 10×
objective.
Matrix degradation assay
MTLn3 CXCR4 or MTLn3 CXCR4-CXCR7 GFP labeled
cells were plated overnight on MatTek dishes, at 1 ×
105 cells/dish, over a thin Alexa 405-gelatin matrix in
the presence of the protease inhibitor GM6001 (10 μm).
Cells were subsequently starved for three hours, washed
three times in starvation media [37] and stimulated with
5 nM CXCL12 for six hours. At the end of the incuba-
tion time, cells were fixed in 3.7% paraformaldehyde and
imaged. The images were processed using the ImageJ
Spot enhancing filter 2D (3.0 pixels Gaussian filter) and
the threshold levels set to select only degradation areas.
The degradation area was normalized to the cell cover-
age area in the GFP channel. Alexa405 (A30000, Invitro-
gen, Grand Island, NY, USA) was conjugated to gelatin
(G2500, Sigma, St. Louis, MO, USA) and thin matrix
Alexa405-gelatin matrix was prepared as previously
described [38]. Results are reported as the degraded
area/cell area per field normalized to the MTLn3
CXCR4 unstimulated levels.
In vivo invasion
All animal procedures were conducted observing the
National Institutes of Health regulations on the use and
care of experimental animals. Our animal protocol was
approved by the Albert Einstein College of Medicine ani-
mal use committee. Female severe combined immunode-
ficiency (SCID) mice aged four to seven weeks from NCI
were used for all experiments. To form primary tumors,
MTLn3 transductants grown to 70 to 85% confluency
were detached using PBS without Ca2+/Mg2+ + 2 mM
EDTA, resuspended in cold PBS supplemented with 0.2%
BSA to inject 5 × 105 cells per animal in a 100 μl volume.
Cells were injected into the fourth mammary fat pad and
tumors allowed to grow until they reached an average
volume of 1,300 mm3 for the in vivo invasion assay. Mice
were anesthetized using isoflurane and blocking needles
placed into the primary tumors using micromanipulators
(MN-151; Narishige, East Meadow, NY, USA). Hamilton
33 gauge needles were loaded with a mixture of EDTA,
10% matrigel and CXCL12 dissolved in L15-0.35% BSA,
and these experimental needles used in place of the
blocking needles after the animal was appropriately
setup. Detailed information about this assay can be found
in [39]. To block the colony stimulating factor 1 (CSF-1)
receptor on the mouse tumor associated macrophages we
used the anti-mouse CSF-1R antibody (AFS98) [40] at 15
μg/ml; to block epidermal growth factor (EGF)-derived
from the mouse tumor associated macrophages from
binding to EGF receptor (EGFR) we used a neutralizing
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EGF antibody at a concentration of 20 μg/ml (AF2028;
R&D systems, Minneapolis, MN, USA). An isotype IgG
antibody (012-000-007 or 111-005-144, Jackson Immu-
noResearch, West Grove, PA, USA) was used at the same
concentration as the blocking/neutralizing antibodies as
a control. To inhibit CXCR4 we used 100 nM AMD3100.
Cells were allowed to invade into the needles for four
hours and the contents of the needles were subsequently
extruded into coverslips, invasive cells stained with 4’,6-
diamidino-2-phenylindole (DAPI) and counted using an
Inverted Olympus IX70 microscope (Center Valley, PA,
USA).
Intravital imaging
Primary tumors of an average volume of 1,300 mm3
were used for intravital imaging. Mice were anesthetized
with isoflurane and a skin-flap surgery carefully per-
formed to expose the primary tumor while minimizing
damage to tissue and blood vessels. Animals were placed
on the stage of an inverted microscope and the GFP-
labeled carcinoma cells imaged using an Olympus Fluo-
view FV1000-MPE microscope (Center Valley, PA, USA)
at an excitation of 880 nm with a 25 × 1.05 NA water
objective. Collagen fibers were visualized by second har-
monic generation. Time-lapse Z-series were taken at 5
μm steps for a total of 100 μm into the tumor over 30
minutes at two-minute intervals. Movies were analyzed
using Image J http://imagej.nih.gov/ij/. A cancer cell was
considered to be motile when it had protruded/translo-
cated at least half a cell length, and the total number of
motile cancer cells in a 50 μm Z-stack time-lapse movie
was determined. A more detailed description of this
protocol can be found in [41].
Spontaneous metastasis and intravasation
Primary tumors were allowed to grow until they reached
an average volume of 1,500 mm3 to perform end-point
metastasis assays. At this time, mice were anesthetized
using isoflurane and blood collected via cardiac puncture
from the right side of the heart to obtain cancer cells that
had intravasated. The blood drawn was then plated into a
10 cm dish with alpha MEM supplemented with 5% FBS/
0.5% P/S, and cancer cell colonies allowed to grow for a
week in a 37°C incubator followed by counting using a
light microscope. Tumor blood burden is reported as the
total number of cancer cell colonies present in a dish
normalized to the volume of blood plated. Lungs and pri-
mary tumors were harvested and fixed in 10% formalin
solution. The lungs were paraffin-embedded, sectioned
and stained with H&E to count the number of lung
metastasis present in all lobes of a single section using a
light microscope with a 10× objective. To evaluate lymph
node metastasis, both axillary and inguinal lymph nodes
were removed from tumor-bearing mice, fixed in 10%
formalin solution, paraffin-embedded, sectioned and
stained with H&E. The presence of metastases was
assessed using a Nikon Labophot light microscope (Mel-
ville, NY, USA). To estimate bone marrow metastasis,
the femur ipsilateral to the site of primary tumor growth
was dissected and bone marrow was flushed using 1 ml
syringes with 25-gauge needles into a 10 cm plate con-
taining alpha MEM supplemented with 5% FBS/0.5% P/S.
Plates were incubated at 37°C for a week and tumor colo-
nies then counted.
Immunohistochemistry
For microvessel density evaluation, formalin-fixed, paraf-
fin-embedded sections from MTLn3 JP, MTLn3
CXCR4, MTLn3 CXCR7, and MTLn3 CXCR4-CXCR7
primary tumors were deparaffinized, rehydrated, blocked
in donkey serum and stained with rat antimouse CD34
antibody (CL8927AP; Cedarlane labs, Burlington, NC,
USA) at a 1:400 dilution for one hour. Slides were
washed and subsequently stained with a biotinylated
antirat secondary antibody for 50 minutes. The slides
were rinsed and exposed to ABC-HRP (PK-6100, Vec-
tor, Burlingame, CA, USA) for 20 minutes, washed and
exposed to diaminobenzidine (DAB) for one to four
minutes (SK-4100, Vector, Burlingame, CA, USA), and
subsequently counterstained with Harris hematoxylin
(s212, Poly-scientific, Bay Shore, NY, USA), rinsed and
mounted. Mean vessel density was determined by count-
ing the number of blood vessels present per field seen in
a light microscope using a 10× objective. A total of
three different primary tumors were used per cell line,
counting five fields per tumor. For VEGFA evaluation,
samples for immunohistochemistry (IHC) were sec-
tioned at 5 μm, deparaffinized in xylene followed by
graded alcohols. Antigen retrieval was performed in 10
mM sodium citrate buffer at pH 6.0, heated to 96C, for
20 minutes. Endogenous peroxidase activity was
quenched using 3% hydrogen peroxide in PBS for 10
minutes. Blocking was performed by incubating sections
in 5% normal donkey serum with 2% BSA for one hour.
The primary antibody to VEGFA, (PAB12284,
ABNOVA, Walnut, CA, USA) was used at 1:250 for 1.5
hours at room temperature. The primary species (rabbit
IgG) was substituted for the primary antibody to serve
as a negative control. The sections were stained by rou-
tine IHC methods, using HRP rabbit polymer conjugate
(Invitrogen, Grand Island, NY, USA), for 20 minutes to
localize the antibody bound to antigen, with diamino-
benzidine as the final chromogen. All immunostained
sections were lightly counterstained with hematoxylin.
Statistical analysis
Analysis of variance (ANOVA) was used to demonstrate
that there were significant differences between
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conditions when there were more than two conditions,
and paired analyses were performed using either student
t-test, or Mann-Whitney test in order to identify the
conditions that were significantly different. Correlation
of MMP12 expression with CXCR4 and CXCR7 was
performed using Oncomine with the following data-
bases: Bittner Breast, Bonnefoi Breast, Desmedt Breast,
Ginestier Breast, Gluck Breast, Hess Breast, Ivshina
Breast, Loi Breast, and van’t Veer Breast. SPSS was used
to determine correlation coefficients and their signifi-
cance from the downloaded expression data. The Onco-
mine database was also used to identify clinical
parameters with which MMP12 mRNA levels were sig-
nificantly correlated. The following parameters were
examined: estrogen receptor (ER) positive, triple nega-
tive, high grade, metastasis, recurrence and survival. The
probabilities of overexpression or underexpression of
MMP12 for all breast cancer datasets containing more
than 40 samples for which the parameters were pro-
vided by Oncomine were downloaded. For each para-
meter, the number of datasets in which the probability
of MMP12 overexpression or underexpression was less
than 0.05 was identified and the binomial cumulative
probability distribution was used to determine the likeli-
hood of that number occurring by chance using SPSS
(IBM, Armonk, NY).
Results
CXCR7 enhances in vitro chemotaxis to CXCL12 in the
presence of high CXCR4
To evaluate the roles of CXCR4 and CXCR7 in
CXCL12-induced chemotaxis in vitro, the human open
reading frames of these receptors were stably overex-
pressed in the rat mammary adenocarcinoma cell line
MTLn3 using retroviral expression vectors. RT-PCR of
these cell lines demonstrates clear increases in mRNA
for the corresponding receptors (Figure 1a). A low level
of endogenous rat CXCR4 mRNA expression in the
MTLn3 cell line was confirmed by quantitative real-time
PCR showing a Ct of 35 cycles (GAPDH Ct of 16). The
levels of expression of CXCR4 and CXCR7 at the cell
membrane were subsequently evaluated using FACS
analysis (Figure 1b). Staining with a control isotype anti-
body is represented by a grey shaded peak in all plots.
The MTLn3 JP empty vector control cell line shows low
levels of expression of CXCR4 (solid line) with little
expression of CXCR7 (dashed line), consistent with the
PCR data. The CXCR4 transductant, MTLn3 CXCR4,
shows higher expression of CXCR4 (solid line), while
the CXCR7 transductant, MTLn3 CXCR7, shows higher
expression of the CXCR7 receptor (dashed line). The
levels of both CXCR4 and CXCR7 expression in the
double transductant, MTLn3 CXCR4-CXCR7, show
increases comparable with the respective single
transductants. Mean fluorescence intensity values for
the different transductants are included in Additional
data file 1. The observed low levels of endogenous rat
CXCR4 expression in the MTLn3 transductants were
confirmed using a different antibody against full length
rat CXCR4 [see Additional data file 2]. Although there
is a slight increase in the surface expression of CXCR4
in the CXCR7 cell lines compared with control JP lines
(Figure 1b) [see Additional data file 1] this was not evi-
dent in the subsequent FACS analysis using the rat spe-
cific CXCR4 antibody [see Additional data file 2], and
did not produce any increase in CXCL12-induced che-
motaxis compared with the JP control line (see below).
In summary, we were able to increase the expression of
both CXCR4 and CXCR7 at least three fold over the
basal expression levels.
Having engineered MTLn3 cell lines overexpressing
either CXCR4, CXCR7, or both receptors, we compared
their chemotaxis to CXCL12 using a microchemotaxis
chamber (Figure 1c). The MTLn3 CXCR4 cell line
showed significantly increased CXCL12-induced chemo-
taxis (P < 0.005) compared with the control cell line,
MTLn3 JP. The MTLn3 CXCR7 cell line showed no
chemotactic response to CXCL12 (P > 0.1). Further-
more, overexpression of both CXCR4 and CXCR7
resulted in a significantly increased chemotactic
response to CXCL12 compared with that of the MTLn3
CXCR4 cell line (P < 0.005). This migration phenotype
suggests that although CXCR7 alone does not mediate
CXCL12-induced motility, in the presence of CXCR4,
CXCR7 augments CXCL12-stimulated motility. This
was confirmed in the cancer cell line MDA-MB-435
previously shown to express low endogenous levels of
CXCR4 [42] [see Additional data file 2], which also
showed the CXCR4-CXCR7 double overexpressors to
have the most chemotaxis to CXCL12.
To test whether the increased motility observed in the
MTLn3 CXCR4-CXCR7 cell line was dependent on
CXCR4, we added the CXCR4 inhibitor, AMD3100, at a
concentration that specifically inhibits CXCR4 without
acting as an agonist of CXCR7 [43]. Addition of
AMD3100 significantly decreased CXCL12-induced che-
motaxis of both MTLn3 CXCR4 and MTLn3 CXCR4-
CXCR7 cells (P < 0.005) (Figure 1d) suggesting that
CXCR4 is important for CXCL12-induced chemotaxis in
the double overexpressors. Addition of I-TAC
(CXCL11), a chemokine that binds to CXCR7 [2,22],
failed to act as a chemoattractant or impair CXCL12-
induced chemotaxis for either MTLn3 CXCR4, or
MTLn3 CXCR4-CXCR7 cells (P > 0.5) (Figure 1e). Simi-
larly, addition of the CXCR7 inhibitors CCX771 and
CCX733 did not inhibit chemotaxis to CXCL12 in the
MTLn3 CXCR4-CXCR7 cells (P > 0.4) (Figure 1f).
These results show that in vitro, CXCR7 alone does not
Hernandez et al. Breast Cancer Research 2011, 13:R128
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Figure 1 Expression of CXCR7 increases the in vitro chemotactic response of MTLn3 CXCR4 cells to CXCL12. (a) RT-PCR of RNA isolated
from the indicated transductants using primers specific for either rat GAPDH, rat CXCR4, human CXCR4, or both rat and human CXCR7. (b) FACS
analysis of the transductants. Representative FACS plots show receptor expression at the cell membrane: isotype control mouse IgG (grey shaded
peaks), anti-CXCR4 antibody (solid lines, MAB172) and anti-CXCR7 antibody (dashed lines, 11G8). (c) Chemotaxis of transduced cell lines to
CXCL12. Cells were allowed to chemotax for four hours at 37°C in a microchemotaxis chamber. Total number of cells per well are reported (11
to 33 wells were counted per condition). Comparison of MTLn3 CXCR4 chemotaxis to CXCL12 with that of MTLn3 JP cells shows a statistically
significant increase at 0.25 nM, 1 nM, 10 nM, and 100 nM with a P value less than 0.005 as determined by t-test, and P = 0.079 at 0.05 nM
CXCL12. Comparison of the chemotaxis of the double expressors, CXCR4-CXCR7, with that of MTLn3 JP cells show similarly statistically significant
differences as determined by t-test, with P < 0.05 at 0.05 nM CXCL12 and P < 0.005 at the other concentrations. Statistically significant
differences between MTLn3-CXCR4 and MTLn3 CXCR4-CXCR7 are indicated in the figure with P < 0.05 indicated by * and P < 0.005 indicated by
**. (d) Chemotaxis of MTLn3 CXCR4 and MTLn3 CXCR4-CXCR7 cells to 1 nM CXCL12 with or without 100 nM AMD3100 (6 to 22 wells were
counted per condition), P < 0.005 is represented by **. (e) Chemotaxis of MTLn3 CXCR4 and MTLn3 CXCR4-CXCR7 cells to 1 nM CXCL12 with or
without 10 nM I-TAC (five to seven wells were counted per condition). (f) MTLn3 CXCR4-CXCR7 chemotaxis to 1 nM CXCL12 in the presence of
vehicle DMSO, CCX771, or CCX733 (11 to 15 wells were counted per condition). Means and SEMs are shown.
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mediate CXCL12-induced chemotaxis. However, when
expressed in cells with high levels of CXCR4, CXCR7
augments CXCR4-mediated chemotaxis to CXCL12, in
agreement with recent studies using MDA-MB 231 cells
[36]. Importantly, the chemotaxis response of the double
overexpressors, CXCR4-CXCR7, was impaired in the
presence of CXCR4 inhibitor, AMD3100, but not upon
addition of ITAC or the CXCR7 inhibitors CCX771 or
CCX733 suggesting that binding of CXCL12 to CXCR4
but not CXCR7 is needed for chemotaxis to occur.
CXCR7 inhibits invasion to CXCL12
We next tested the role of these receptors in CXCL12-
induced invasion in vitro using transwells precoated
with Matrigel. Although overexpression of CXCR4,
CXCR7, or both CXCR4 and CXCR7 did not affect
MTLn3 basal invasion in vitro as measured in the pre-
sence of just buffer (P > 0.6) (Figure 2a, gray bars),
CXCR4 expression enabled an invasive response of
MTLn3 cells to CXCL12 in vitro (P < 0.05). CXCR7
expression alone failed to significantly enhance invasion
to CXCL12 (P = 0.9). Surprisingly, in the context of
CXCR4 overexpression, CXCR7 inhibited CXCL12-
induced invasion compared with MTLn3 CXCR4 cells
(P < 0.05).
To measure the effects of CXCR4 and CXCR7 overex-
pression on invasion in response to CXCL12 in vivo, we
injected MTLn3 JP, MTLn3 CXCR4, MTLn3 CXCR7,
and MTLn3 CXCR4-CXCR7 cell lines labeled with GFP
into the fourth mammary fat pads of SCID mice and
allowed the tumors to grow until they reached an aver-
age volume of 1,300 mm3 for in vivo invasion analysis.
FACS analysis of the primary tumors confirmed that
overexpression of CXCR4 and CXCR7 in the respective
cell lines was conserved in vivo [see Additional data file
3]. Needles containing Matrigel and CXCL12 as a che-
moattractant were inserted in the primary tumors and
invasive cells collected for a four-hour period. Overex-
pression of CXCR4 dramatically increased the in vivo
invasive behavior of MTLn3 cells to CXCL12, with peak
invasion shifted to lower concentrations (Figure 2b).
CXCR7 overexpression alone, however, did not enhance
the ability of MTLn3 cells to invade in response to
CXCL12, as they failed to invade in vivo at the highest
concentration of CXCL12 (62.5 nM) tested compared
with buffer levels, a concentration which induced a
three-fold increase in invasion above background in the
MTLn3 JP tumors. Similarly, expression of CXCR7 in
the presence of CXCR4 also impaired the invasive
response to CXCL12 at all concentrations, with the peak
response at 15.6 nM being significantly reduced in the
MTLn3 CXCR4-CXCR7 tumors (P < 0.005). Invasion in
response to 6.25 nM CXCL12 was not tested for the
MTLn3 CXCR7 strain since responses to the higher
concentrations were similar to the buffer response and
the in vitro chemotaxis data did not demonstrate any
response at lower concentrations. These results are con-
sistent with the in vitro invasive behavior of these cell
lines, confirming that CXCR7 plays a negative role in
CXCL12-induced invasion. The relatively weak in vivo
invasive response seen at 15.6 nM CXCL12 in the
MTLn3 CXCR4-CXCR7 cell line is significantly
impaired upon addition of the CXCR4 inhibitor
AMD3100 (P < 0.05; Figure 2c), indicating the remain-
ing response is still mediated by CXCR4. As there is no
increase in CXCR4 expression seen in the MTLn3 JP
tumor cells [see Additional data file 3], the response
seen in MTLn3 JP tumors to high levels of CXCL12
may reflect initiation of the paracrine loop by tumor-
associated macrophages, which express CXCR4 [44-46].
These data show that CXCR7 expression alone plays
no role in CXCL12-induced motility (chemotaxis or
invasion). However, CXCR7 expression in the context of
high levels of CXCR4, while enhancing chemotaxis to
CXCL12, impairs invasion in vitro and in vivo to
CXCL12. These results raised the possibility that
CXCR7 inhibits the ability to degrade extracellular
matrix in response to CXCL12 stimulation and hence
invasion. To address this, we measured the ability of
MTLn3 CXCR4 and MTLn3 CXCR4-CXCR7 cells to
degrade fluorescently labeled matrix (Figure 2d).
Although there was no significant difference in the abil-
ity of these cell lines to degrade matrix in the absence
of stimulation, when exposed to CXCL12 only the
CXCR4 overexpressors showed significantly increased
degradation (P < 0.05), while the double overexpressors
showed no increase, indicating that CXCR7 expression
impairs CXCL12-induced invasion by suppressing
CXCL12-induced matrix degradation. Evaluation of the
expression of different MMPs (MMP1, MMP2, MMP3,
MMP7, MMP9-14) at the mRNA level revealed that
MMP12 was significantly higher in the CXCR4 line
compared with the other lines after stimulation with
CXCL12 (P < 0.01 by ANOVA) [see Additional data file
4]. Western blotting after CXCL12 stimulation also indi-
cated that MMP12 expression was highest in the
CXCR4 line [see Additional data file 4]. These results
suggest that there is differential regulation of MMPs in
the MTLn3 CXCR4 and CXCR4-CXCR7 cells upon
CXCL12 stimulation with the CXCR4-expressing cells
showing increased expression of MMPs such as MMP3,
MMP10, and MMP12. Evaluation of breast cancer data
present in the Oncomine database indicates that only
MMP12 expression is significantly correlated with
CXCR4 expression: from the nine breast cancer data-
bases evaluated, the average correlation was 0.31 with
an average P value for the correlation of less than 0.04.
In the same databases, the average correlation of
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MMP12 with CXCR7 was -0.03, which was not signifi-
cant (P < 0.46).
We had previously reported that CXCL12 could
induce in vivo invasion in the MMTV-PyMT transgenic
breast cancer model, and that this invasion was depen-
dent on the EGF/CSF-1 paracrine loop between cancer
cells and macrophages where CSF-1 is secreted by can-
cer cells and stimulates macrophages to produce EGF
[21]. To test whether CXCL12 induced in vivo invasion
in the MTLn3 CXCR4 model was also dependent on
EGF/CSF-1 signaling, we tested the ability of these cells
to invade in vivo in response to CXCL12 in the presence
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Figure 2 CXCR4 expression enhances CXCL12 induced invasion, while CXCR7 expression impairs it. (a) In vitro invasion of MTLn3 JP,
MTLn3 CXCR4, MTLn3 CXCR7, and MTLn3 CXCR4-CXCR7 cells in the presence or absence of 10 nM CXCL12. The total number of invasive cells
present per filter were counted and normalized to the invasive response of control MTLn3 JP cells in the absence of CXCL12 stimulation (n = 3
individual experiments per condition). (b) In vivo invasion of MTLn3 JP, MTLn3 CXCR4, MTLn3 CXCR7, and MTLn3 CXCR4-CXCR7 primary tumors
in response to the indicated concentrations of CXCL12. Cells were allowed to invade for four hours into needles containing Matrigel plus or
minus chemoattractant. Note that the buffer measurements for all transductants are plotted and overlap. For the MTLn3 CXCR7 transductant,
there is no measurement at 6.25 nM CXCL12 as there were no responses at higher concentrations of CXCL12 and the chemotaxis data showed
no response at low concentration of CXCL12. Data are from 10 mice with three to eight needles per condition for MTLn3 JP, 14 mice with 5 to
10 needles per condition for MTLn3 CXCR4, eight mice with three to six needles per condition for MTLn3 CXCR7, 13 mice with three to eight
needles per condition for MTLn3 CXCR4-CXCR7. Comparison of MTLn3 CXCR7 invasion to CXCL12 with that of MTLn3 JP cells show statistically
significant reduction at 31.25 nM (P < 0.05) and 62.5 nM (P < 0.005) using t-test. Comparison between MTLn3 CXCR4 and MTLn3 JP invasion
shows statistically significant differences at 6.25 nM, 15.6 nM and 31.25 nM CXCL12 with P < 0.05, P < 0.005, and P < 0.05, respectively. MTLn3
CXCR4-CXCR7 tumors showed statistically significant decreased invasion at all concentrations of CXCL12 tested compared to MTLn3 CXCR4 6.25
nM P < 0.05, 15.6 nM P < 0.005, 31.25 nM P < 0.005, 62.5 nM P < 0.05. (c) In vivo invasion of MTLn3 CXCR4-CXCR7 tumors in response to 15.6
nM CXCL12 with or without 100 nM AMD3100. Three animals were tested with three to seven needles counted per condition. (d) Matrix
degradation of MTLn3 CXCR4 and MTLn3 CXCR4-CXCR7 cells in the absence or presence of 5 nM CXCL12 (at least 19 fields were counted per
condition). Means and SEMs are shown. P < 0.05 is represented by * as determined by t-test.
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of either a neutralizing EGF antibody or a blocking CSF-
1R antibody [40]. The MTLn3 CXCR4 invasive response
to CXCL12 was significantly impaired in the presence of
either antibody [see Additional data file 5], indicating
EGF/CSF-1 signaling is required for CXCL12 induced in
vivo invasion in this model. Thus CXCR4 overexpres-
sion did not override the dependency of these breast
cancer cells on the EGF/CSF-1 paracrine loop for in
vivo invasion.
CXCR4 overexpression stimulates cancer cell motility
within the primary tumor
Given the difference in the in vitro chemotactic and
invasive behavior in response to CXCL12 stimulation of
the double overexpressors, MTLn3 CXCR4-CXCR7, we
proceeded to evaluate their motile behavior within the
tumor microenvironment. The GFP labeled MTLn3
transductants were orthotopically injected in SCID mice
and the tumors used for intravital imaging when they
had reached an average volume of 1,300 mm3. Time-
lapse z-series were taken using multiphoton microscopy
to evaluate the number of cancer cells moving within
the tumor microenvironment. Similar to the in vitro
invasion results, CXCR4 overexpression significantly
enhanced the motile behavior of MTLn3 cells within the
primary tumor - about three-fold compared with
MTLn3 JP cells (P < 0.005; Figure 3a). CXCR7 overex-
pression alone did not have a significant effect on can-
cer cell motility within the primary tumor compared
with MTLn3 JP (P = 0.18). The double overexpressors,
MTLn3 CXCR4-CXCR7, showed an intermediate phe-
notype that was greater than MTLn3 JP intravital moti-
lity (P < 0.05), but reduced compared with MTLn3-
CXCR4 (P = 0.06). Representative images of cancer cell
motility in each tumor are shown (Figure 3b) with
representative movies included as Additional data files
6,7,8 to 9. In summary, the motile behavior of the differ-
ent transductants in vivo most closely resembled their in
vitro invasive response to CXCL12. Namely, while
CXCR4 overexpression enhanced the motility of MTLn3
cells within the tumor, CXCR7 overexpression alone
had no effect and in the context of CXCR4 overexpres-
sion, high levels of CXCR7 resulted in decreased moti-
lity. This suggests that despite the increased chemotactic
response of the CXCR4-CXCR7 expressors to CXCL12
in vitro, their ability to invade extracellular matrix is
impaired by their reduced degradation potential.
CXCR7 overexpression enhances primary tumor growth
while CXCR4 enhances intravasation
As CXCR4 and CXCR7 have been found to play a role
in breast cancer growth and metastasis, we tested the
effects of CXCR4 and CXCR7 overexpression on pri-
mary tumor growth, intravasation and lung metastasis
formation of MTLn3 cells. Comparison of the volumes
of MTLn3 CXCR4 tumors to the control MTLn3 JP
tumors showed no difference (P = 0.38; Figure 4a), indi-
cating that CXCR4 overexpression does not enhance
growth of MTLn3 tumors. On the other hand, MTLn3
CXCR7 tumors showed significantly increased tumor
size compared with the control MTLn3 JP tumors (P <
0.05), and similarly the MTLn3 CXCR4-CXCR7 double
overexpressors were significantly bigger than either
MTLn3 JP or MTLn3 CXCR4 tumors (P < 0.05); indi-
cating that CXCR7 but not CXCR4 plays a role in
enhancing tumor growth. Comparison of sizes of
CXCR7 and CXCR4 tumors indicated a trend towards
significance (P < 0.062). MTLn3 cells expressing CXCR7
alone or coexpressed with CXCR4-formed tumors that
were visible macroscopically by day 12, while the control
JP and CXCR4 expressing tumors were not visible until
day 15 (data not shown). Importantly, we did not see a
difference in the growth of these cell lines in vitro (data
not shown). However, in line with previous reports
[23,27], we observed increased blood vessel density in
MTLn3 CXCR7 and MTLn3 CXCR4-CXCR7 primary
tumor sections compared with control MTLn3 JP (P <
0.005) and MTLn3 CXCR4 tumors (P < 0.05), respec-
tively (Figure 4b) using a CD34 antibody, suggesting
that CXCR7 overexpression increases the growth of the
primary tumor by stimulating angiogenesis. MTLn3
CXCR4 tumors showed blood vessel density comparable
with that of MTLn3 JP tumors (P = 0.9). Previous stu-
dies have shown that CXCR7 expression can stimulate
angiogenesis by inducing the secretion of VEGF [23,27].
Consistent with those studies, we found that VEGFA
(Vascular endothelial growth factor A) expression is
increased in MTLn3 CXCR7 and CXCR4-CXCR7 pri-
mary tumors compared to either MTLn3 JP or CXCR4
tumors (Figure 4c).
We next evaluated the effects of CXCR4 and CXCR7
overexpression on the process of intravasation, by doing
intracardiac punctures prior to euthanization of mice
carrying tumors of an average volume of 1,500 mm3. As
shown in Figure 4d, MTLn3-CXCR4 cells were signifi-
cantly more efficient in entering the bloodstream com-
pared with MTLn3-JP and CXCR4-CXCR7. Both
MTLn3 CXCR7 and MTLn3 CXCR4-CXCR7 tumor
models showed low numbers of intravasated cancer
cells. These results agree with the increased invasive and
motile behavior of the CXCR4 overexpressing MTLn3
cells seen within the primary tumor, and the impaired
ability of the CXCR7 overexpressors to invade in vivo.
To compare the ability of the MTLn3 transductants to
spontaneously metastasize from the primary tumor to
the lung, we evaluated lung metastasis formation in ani-
mals that had been injected in the mammary fat pad
with the transduced MTLn3 cells. Lungs were harvested
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Figure 3 Overexpression of CXCR4 enhances MTLn3 motility within the primary tumor. GFP labeled MTLn3 transductants were
orthotopically injected in the fourth mammary fat pad of SCID mice. Primary tumors with an average volume of 1,300 mm3 were imaged using
multiphoton microscopy. (a) Quantitation of the motility events observed in each tumor type. The average number of motile cancer cells (GFP
positive) in a 50 μm Z-stack time-lapse series per movie is reported. Six MTLn3 JP animals were imaged with a total of 20 movies analyzed, four
MTLn3 CXCR4 animals were imaged with 17 movies analyzed, four MTLn3 CXCR7 and four MTLn3 CXCR4-CXCR7 animals were imaged with 13
and 14 movies analyzed respectively. Means and SEMs are shown. MTLn3 JP vs. MTLn3 CXCR4 (a) P < 0.005; MTLn3 JP vs. MTLn3 CXCR4-CXCR7
(b) P < 0.05 with P values determined using Mann-Whitney. Scale bar: 10 μm. (b) Representative images of the motility observed in the
indicated tumors, GFP tumor cells appear as green cells, host cells as dark shadows and ECM in purple. Individual frames are 10 minutes apart.
Motile cancer cells are indicated by arrowheads.
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Figure 4 Opposing roles of CXCR4 and CXCR7 in primary tumor growth, intravasation and lung metastasis formation. (a) Primary
tumor volumes at 30 to 34 days post orthotopic injection of MTLn3 JP (21 mice), MTLn3 CXCR4 (20 mice), MTLn3 CXCR7 (19 mice), and MTLn3
CXCR4-CXCR7 (29 mice). MTLn3 JP vs. MTLn3 CXCR7 (a) P < 0.05; MTLn3 JP vs. MTLn3 CXCR4-CXCR7 (b) P < 0.05; MTLn3 CXCR4 vs. MTLn3
CXCR4-CXCR7 (c) P < 0.05 with P values determined using Mann Whitney. (b) CXCR7 overexpression increases angiogenesis of MTLn3 tumors.
MTLn3 JP, MTLn3 CXCR4, MTLn3 CXCR7, and MTLn3 CXCR4-CXCR7 primary tumors were harvested when they reached an average volume of
1,100 mm3, fixed and paraffin embedded. Immunohistochemistry to stain blood vessels was done using an antimouse CD34 antibody. Three
tumors were used per cell line, with five fields counted per tumor. Representative images are shown (top), scale bar 100 μm, with the respective
quantitation of mean vessel density (MVD, bottom). Student’s t-test was used for two-condition comparisons and confirmed with ANOVA; MTLn3
JP vs. MTLn3 CXCR7 (a) P < 0.005; MTLn3 JP vs. MTLn3 CXCR4-CXCR7 (b) P < 0.05; MTLn3 CXCR4 vs. MTLn3 CXCR4-CXCR7 (c) P < 0.005. VEGFA
immunohistochemistry of MTLn3 JP, MTLn3 CXCR4, MTLn3 CXCR7, and MTLn3 CXCR4-CXCR7 primary tumors. Three tumors were used per cell
line with one representative tumor being shown, scale bar 200 μm. Staining in all samples is significantly greater than that seen with control
staining with a nonspecific primary antibody (data not shown). Scale bar: 200 μm. (d) Intravasation of the different MTLn3 transductants
measured using a blood burden assay. The total number of cancer cell colonies present were counted and normalized to the total volume of
blood collected. MTLn3 JP n = 21 mice, MTLn3 CXCR4 n = 20 mice, MTLn3 CXCR7 n = 10 mice, MTLn3 CXCR4-CXCR7 n = 17 mice. MTLn3 JP vs.
MTLn3 CXCR4 (a) P < 0.05; MTLn3 CXCR4 vs. MTLn3 CXCR4-CXCR7 (b) P < 0.005 with P values determined using Mann-Whitney. (e)
Spontaneous lung metastasis formation of the MTLn3 transductants. The different cell lines were injected into the mammary fat pad and lungs
harvested once the primary tumors reached an average volume of 1,500 mm3. MTLn3 JP n = 19 mice, MTLn3 CXCR4 n = 20 mice, MTLn3 CXCR7
n = 16 mice, MTLn3 CXCR4-CXCR7 n = 29 mice. The total number of lung metastases present in all lung lobes of a single H&E section are
reported. MTLn3 JP vs. MTLn3 CXCR7 (a) P < 0.005; MTLn3 JP vs. MTLn3 CXCR4-CXCR7 (b) P < 0.005; MTLn3 CXCR4 vs. MTLn3 CXCR4-CXCR7 (c)
P < 0.005. Means and SEMs are shown.
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when the primary tumors reached an average volume of
1,500 mm3, fixed, paraffin-embedded and sectioned to
count the number of metastases present per H&E sec-
tion. The number of spontaneous lung metastases pre-
sent in the MTLn3 CXCR4 model was not significantly
different to the number of lung metastases formed in
the empty vector control model, MTLn3 JP (P = 0.3 stu-
dent’s t-test and P = 0.8 Mann-Whitney; Figure 4e), nor
was there any difference in the size of the metastases
(data not shown). This was an unexpected result as
MTLn3 CXCR4 cells were more efficient in leaving the
primary tumor and entering the bloodstream compared
with MTLn3 JP cells, thus we looked for metastasis for-
mation in the bone and lymph nodes but no difference
was observed at these sites (P = 0.7 and P = 0.8, respec-
tively) [see Additional data file 10]. However, the
MTLn3 CXCR7 tumors gave rise to significantly fewer
lung metastases compared with the empty vector model,
MTLn3 JP, (a, P < 0.005) and likewise, the double over-
expressors, MTLn3 CXCR4-CXCR7, showed decreased
lung metastasis compared with both MTLn3 JP (b, P <
0.005) and MTLn3 CXCR4 (c, P < 0.005; Figure 4e). No
significant difference in size of lung metastasis, or in
bone or lymph node metastasis was observed in the dif-
ferent CXCR7 transductants compared with control
MTLn3 JP or MTLn3 CXCR4 (data not shown) [see
Additional data file 10].
Discussion
Previous studies have reported that both CXCR4 and
CXCR7 play roles in breast cancer growth and metasta-
sis, with both receptors being implicated in primary
tumor growth, invasion and metastasis formation
[2,6,10,12,22]. However, distinguishing the roles of these
receptors in the early steps of metastasis has not been
performed. Using the rat mammary adenocarcinoma cell
line MTLn3, we studied the effects of overexpression of
CXCR4 and CXCR7 on CXCL12-induced chemotaxis
and invasion, as well as in vivo motility, intravasation
and metastasis formation. We show that CXCR4 overex-
pression increases chemotactic and invasive behavior,
both in vitro and in vivo, in response to a CXCL12 gra-
dient, as well as enhances the motile behavior of tumor
cells within the primary tumor and their ability to intra-
vasate. Expression of CXCR7 alone had no effect on
chemotaxis or invasion in vitro, but suppressed
CXCL12-induced invasion in vivo, as well as intravasa-
tion and metastasis. Expression of both CXCR4- and
CXCR7-enhanced chemotaxis to CXCL12 in vitro, but
CXCL12-induced invasion in vivo and in vitro was
reduced compared with that of cells expressing CXCR4
alone, and metastasis was also reduced.
The increased chemotactic response seen in vitro upon
expression of CXCR4 is consistent with many previous
studies demonstrating that CXCR4 can mediate chemo-
taxis to CXCL12 [47]. The literature on the ability of
CXCR7 to mediate chemotactic responses is mixed, with
some reports suggesting that CXCR7 can mediate che-
motactic responses [1] and others indicating that it can-
not [2,29]. Our data are consistent with the latter studies;
using two cell lines (MTLn3 and MDA-MB-435) that
show little chemotactic response to CXCL12 on their
own, we find that expression of CXCR7 alone does not
enhance chemotactic responses to CXCL12. However,
coexpression of CXCR7 and CXCR4 resulted in increased
chemotaxis towards CXCL12 compared with cells
expressing CXCR4 alone. These data agree with a recent
study showing that increased expression of CXCR7 in
MDA-MB-231 cells results in enhanced chemotaxis to
CXCL12 [36]. AMD3100, a CXCR4 selective inhibitor,
inhibited CXCL12-induced chemotaxis and invasion of
both MTLn3 CXCR4 and MTLn3 CXCR4-CXCR7 cells,
while inhibition of CXCL12 binding to CXCR7 using I-
TAC, CCX733 or CCX771 had no effect on CXCL12-
induced chemotaxis. This indicates that CXCL12 binding
to CXCR4 is needed for the chemotactic response but
that binding of CXCL12 to CXCR7 is not necessary. The
potentiation of the chemotactic response by CXCR7 is
potentially through regulation of downstream signaling
by CXCR4. CXCR7 has been shown to heterodimerize
with CXCR4 [33-35] and to regulate recruitment of b-
arrestin 2, as well as enhance ERK and p38 signaling in
response to CXCL12 stimulation [36,48]. Our results
suggest that although CXCR7 has been shown to alter
Gai coupling to CXCR4 [34], the enhancement of b-
arrestin signaling by CXCR7 [36] is more significant,
resulting in enhanced chemotactic responses. It has been
shown that CXCR7 can act as a scavenger receptor that
internalizes CXCL12 and in that way decreases binding
of CXCL12 to CXCR4 [49,50], therefore downregulating
CXCR4 signaling. This has been proposed as a mechan-
ism for suppression of chemotaxis to CXCL12 at low
concentrations of CXCL12 [34]. Under our chemotaxis
conditions, the double overexpressors showed increased
chemotactic behavior in vitro to CXCL12 compared with
the CXCR4 overexpressors even at low CXCL12 concen-
trations, suggesting that the scavenging function was not
reducing chemotaxis in vitro. It is possible that under our
in vitro conditions (in which there is a large volume in
the attractant well, which is unlikely to be depleted dur-
ing the time scale of the experiment) the scavenging
function could actually increase chemotactic responses
by reducing the amount of CXCL12 that leaks past the
cells into the buffer side, and thereby maintaining a stee-
per gradient [51].
However, we found that coexpression of CXCR7 with
CXCR4 did impair CXCL12-induced invasion in vitro of
MTLn3 CXCR4 cells. CXCR7 potentially could
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modulate CXCR4 regulated gene expression by signaling
through b-arrestin 2 [30,32,34]. This might result in
decreased ability to degrade extracellular matrix, which
could translate into a defect in invasion but not chemo-
taxis. Indeed this seems to be the case as the double
overexpressors showed significantly reduced matrix
degradation in response to CXCL12 treatment com-
pared with the CXCR4 overexpressors. Evaluation of
MMP expression in the MTLn3 transductants showed
increased MMP12 mRNA expression upon CXCL12 sti-
mulation in the MTLn3 CXCR4 cell line compared with
the other transductants including the CXCR4-CXCR7
double expressor. Although MMP3 has been reported to
be induced by CXCR7 [52], we did not observe that in
the MTLn3 lines. Examination of breast cancer studies
in the Oncomine database supports the possibility that
CXCR4 can regulate MMP12 expression: MMP12
expression correlated significantly with CXCR4 expres-
sion, and not with CXCR7 expression. In summary, we
propose that stimulation of CXCR4 can induce expres-
sion of MMP12 to increase invasiveness, and simulta-
neous expression of CXCR7 may suppress this
induction.
The control cell line MTLn3 JP, although failing to
chemotax or invade in vitro in response to CXCL12 sti-
mulation, showed enhanced invasion in vivo at high
concentrations of CXCL12. In addition, expression of
CXCR7 alone reduced the invasion seen at high concen-
trations of CXCL12. As MTLn3 JP did not show chemo-
taxis to CXCL12 at any concentration in vitro and we
did not observe upregulation of CXCR4 expression in
vivo in this control cell line, we believe that the in vivo
invasion at high concentration is a result of stimulating
macrophages (which express CXCR4 [44-46]) within the
tumor microenvironment, which can promote cancer
cell invasion through the paracrine loop [21]. The
reduced in vivo invasion of the CXCR7 expressing cells
could be due to the scavenger function of CXCR7. For
the in vivo invasion assay, CXCL12 diffusion would be
constrained in the compact microenvironment to the
spaces between cells. CXCR7 expressed on the tumor
cells could then scavenge CXCL12, resulting in suppres-
sion of the activation of the invasion response.
The CXCR4 overexpressing line showed a strong in
vivo invasion response to CXCL12, consistent with its
strong chemotaxis and invasion responses in vitro. The
invasion response was mediated by the paracrine loop
with macrophages, as demonstrated by inhibition of
invasion by either blocking EGF or CSF1R signaling.
The CXCR4-CXCR7 line showed a reduced in vivo inva-
sion response, which could reflect a CXCR7-induced
reduction in matrix degradation (as we demonstrated
for in vitro invasion), scavenging of CXCL12 by CXCR7,
or both.
Consistent with previous reports, overexpression of
CXCR7 resulted in a small but statistically significant
increase in primary tumor growth possibly due to
increased angiogenesis [22]. This was correlated with
increased microvessel density and increased VEGFA
expression. VEGFA has been shown to be upregulated
by CXCR7 in a number of tumor cells [23,27,53], and
thus it is likely that the increase in VEGF in the CXCR7
expressing lines leads to increased angiogenesis and
tumor growth. We did not see an effect of CXCR4
expression on primary tumor growth as previously
reported in other breast cancer models [11,12], suggest-
ing that this effect might be cell line specific.
The intravasation efficiencies of the various lines cor-
related with their in vivo invasiveness, with the CXCR4
overexpressing lines showing significantly more intrava-
sation than the other lines. This suggests that CXCL12
signaling could contribute to the intravasation process.
Indeed, perivascular macrophages have been shown to
express CXCL12 [54], and thus a local gradient of
CXCL12 leading towards blood vessels could stimulate
directed invasion around vessels. Thus the CXCR7 lines,
which show reduced invasion to CXCL12 gradients,
would also be reduced in their intravasation capability.
A paradoxical result is our finding that CXCR4 over-
expression did not result in increased spontaneous lung
metastasis formation despite enhancing invasion and
intravasation. This result disagrees with previous studies
suggesting that wild-type or mutant CXCR4 mediates
spontaneous metastasis of breast cancer cells to the
lungs [6,55,56]. However, in those studies, CXCR4 sig-
naling was shown to have a significant effect on primary
tumor growth (or primary tumor size was not provided),
and metastasis was compared at equal times rather than
equal primary tumor sizes, leaving open the possibility
that the increased metastasis seen in those studies
reflects the increased intravasation from a larger primary
tumor. Alternatively, it is possible that the effects of
CXCR4 expression on metastasis varies with the particu-
lar model used, similar to the varying effects on growth.
Our results cannot be explained by impaired cell survi-
val of intravasated cancer cells since the intravasation
assay used in this study evaluated viable cells. One pos-
sibility is that there might be gene expression changes
occurring in MTLn3 CXCR4 cells within the tumor
microenvironment that provide an advantage in entering
the circulation but impair the ability to extravasate or
seed lung metastases. Indeed, MMP12, which we find
upregulated in CXCR4 cells stimulated with CXCL12,
has been shown to be antiangiogenic [57-59]. Thus it is
possible that although MMP12 is helpful in enabling
tumor cells to invade, its antiangiogenic effects suppress
the ability of tumor cells to extravasate and successfully
seed metastases in the lung.
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In summary, our studies provide insight into the com-
plexity of the contributions of CXCR4 and CXCR7 to
tumor cell invasion and metastasis. CXCR4 can enhance
local invasion and intravasation due to CXCL12-induced
chemotaxis and matrix degradation. The ligand scaven-
ging function of CXCR7 may have contrasting effects on
chemotaxis and invasion depending upon the diffusion
constraints imposed upon CXCL12. CXCR7 can affect
tumor growth through increased angiogenesis. We have
identified MMP12 as a potential mediator of CXCR4-
enhanced invasion, and further work will be needed to
test its contributions to the different steps of metastasis.
Conclusions
We have found that CXCR4 and CXCR7 in breast can-
cer cells can make distinct contributions to tumor
malignancy. CXCR4 expression increases tumor cell
invasiveness and motility. CXCR7 expression inhibits
invasion and metastasis, potentially through suppression
of CXCR4 induced expression of MMP12. However,
CXCR7 expression can stimulate VEGFA expression,
microvessel density, and primary tumor growth.
Additional material
Additional file 1: Table 1. Mean fluorescence intensity values were
obtained using FlowJo software with values for CXCR4 and CXCR7
expression normalized to the IgG isotype control for each cell line.
Representative values are shown.
Additional file 2: (a) Endogenous levels of CXCR4 expression. FACS
analysis of the MTLn3 transductants for rat CXCR4 expression using
a rat specific antibody (dotted lines) and isotype control IgG (grey
shaded peaks). (b) FACS analysis of the MDA MB 435 transductants for
CXCR4 and CXCR7 expression with representative plots being shown.
Isotype control mouse IgG (grey shaded peaks), anti-CXCR4 antibody
(dashed lines, MAB172) and anti-CXCR7 antibody (dotted lines, 11G8). (c)
Chemotaxis of the MDA MB 435 transductants to CXCL12 using a
microchemotaxis chamber. Total number of cells per well are reported
(11 to 39 wells were counted per condition). Comparison of 435 CXCR4
chemotaxis to CXCL12 with that of 435 JP cells shows a statistical
significant increase at 1 nM and 5 nM with a P value < 0.05 and < 0.005
respectively, as determined by t-test. Comparison of the chemotaxis of
the double expressors, CXCR4-CXCR7, with that of 435 JP cells shows
similarly statistically significant differences as determined by t-test, with P
< 0.005 at 1 nM and 5 nM CXCL12 and P < 0.05 at 25 nM. Statistical
significant differences between 435 CXCR4 and 435 CXCR4-CXCR7 are
indicated in the figure with P < 0.05 indicated by * and P < 0.005
indicated by **. Means and SEMs are shown.
Additional file 3: FACS analysis of CXCR4 and CXCR7 expression in
MTLn3 cells isolated from primary tumors. MTLn3 JP, MTLn3 CXCR4,
MTLn3 CXCR7, and MTLn3 CXCR4-CXCR7 cell lines labeled with GFP were
injected in the fourth mammary fat pad of female SCID mice. When
tumors reached an average volume of 1,300 mm3, the tumors were
harvested, mechanically disrupted and labeled with either a mouse anti-
CXCR4 antibody (MAB172) or a mouse anti-CXCR7 antibody (11G8). Grey
shaded peaks represent unlabeled primary tumor sample with the peaks
in solid lines representing CXCR4 expression of the carcinoma cells and
the peaks in dashed lines representing CXCR7 expression.
Additional file 4: Expression levels of MMPs in MTLn3 cell lines
stimulated with CXCL12. (a) The indicated MTLn3 cell lines were
stimulated with CXCL12 as described in Methods and then the level of
expression of the indicated MMP was determined by quantitative RT-PCR.
For each experiment, the delta CT vs GAPDH was determined and then
normalized to the MTLn3-CXCR4 value. Higher values correspond to
lower levels of mRNA. The results for MMP2, MMP7, MMP9, and TIMP1
are single experiments which were not repeated because there was no
indication of a difference between the cell lines. For MMP1, MMP3,
MMP10, MMP12, MMP13, MMP14, and TIMP2, the data are means and
SEMS of at least three measurements. (b) Western blotting of extracts of
cells prepared as in a. using an anti-MMP12 antibody (Epitomics 1906-1).
Additional file 5: CXCL12 induced in vivo invasion in MTLn3 CXCR4
tumors requires the EGF/CSF-1 paracrine loop. In vivo invasion of
MTLn3 CXCR4 tumors to CXCL12 in the presence of either a control IgG
antibody (IgG), a blocking CSF-1R antibody (CSF1R Ab) or a neutralizing
EGF antibody (EGF Ab). At least three animals were tested with seven to
eight needles counted per condition. Means and SEMs are shown.
Student’s t-test was used for comparisons, P < 0.05 is represented by *
and P < 0.005 by **.
Additional file 6: Time lapse imaging of MTLn3 JP1520 empty
vector control cells (GFP, green) with extracellular matrix fibers
imaged using second harmonic scattering (purple). Frames were
taken every two minutes, scale bar is 10 μm.
Additional file 7: Time lapse imaging of MTLn3 CXCR4 cells (GFP,
green) with extracellular matrix fibers imaged using second
harmonic scattering (purple). Frames were taken every two minutes,
scale bar is 10 μm.
Additional file 8: Time lapse imaging of MTLn3 CXCR7 cells (GFP,
green) with extracellular matrix fibers imaged using second
harmonic scattering (purple). Frames were taken every two minutes,
scale bar is 10 μm.
Additional file 9: Time lapse imaging of MTLn3 CXCR4-CXCR7 cells
(GFP, green) with extracellular matrix fibers imaged using second
harmonic scattering (purple). Frames were taken every two minutes,
scale bar is 10 μm.
Additional file 10: CXCR4 expression does not increase metastasis
of MTLn3 cells to the bone marrow or lymph nodes. (a)
Spontaneous bone metastasis formation. Bone marrow from the femur
ipsilateral to the primary tumor was extruded into MTLn3 growth media
and cancer colonies present a week after plating counted. The number
of cancer colonies present per femur are reported (P = 0.69, Mann-
Whitney). MTLn3 JP n = 21 mice, MTLn3 CXCR4 n = 30 mice. Means and
SEMs are shown. (b) Axillary and inguinal lymph nodes were dissected
from MTLn3 JP and MTLn3 CXCR4 tumor-bearing mice. Lymph nodes
were fixed, paraffin embedded, sectioned and stained with H&E. The
presence of metastases was assessed using a light microscope with 10×
and 20× objectives. MTLn3 JP n = 13 mice, MTLn3 CXCR4 n = 10 mice,
means and SEMs are shown, P = 0.8, Mann-Whitney.
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